v3.21.2
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited) - USD ($)
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Beginning Balance (in shares) at Dec. 31, 2019   34,274,000    
Beginning Balance at Dec. 31, 2019 $ 3,614,000 $ 3,000 $ 106,188,000 $ (102,577,000)
Equity        
Stock-based compensation expense 328,000   328,000  
Issue stock for warrant exercises (in shares)   3,478,000    
Issue stock for warrant exercises 2,355,000   2,355,000  
Net loss (10,510,000)     (10,510,000)
Ending Balance (in shares) at Mar. 31, 2020   37,752,000    
Ending Balance at Mar. 31, 2020 (4,213,000) $ 3,000 108,871,000 (113,087,000)
Beginning Balance (in shares) at Dec. 31, 2019   34,274,000    
Beginning Balance at Dec. 31, 2019 3,614,000 $ 3,000 106,188,000 (102,577,000)
Equity        
Net loss (18,584,000)      
Ending Balance (in shares) at Jun. 30, 2020   91,975,000    
Ending Balance at Jun. 30, 2020 5,837,000 $ 9,000 126,989,000 (121,161,000)
Beginning Balance (in shares) at Mar. 31, 2020   37,752,000    
Beginning Balance at Mar. 31, 2020 (4,213,000) $ 3,000 108,871,000 (113,087,000)
Equity        
Stock-based compensation expense 328,000   328,000  
Issue common stock, net of issuance costs (in shares)   16,896,000    
Issue common stock, net of issuance costs 16,366,000 $ 2,000 16,364,000  
Issue stock for employee stock purchase plan (in shares)   44,000    
Issue stock for employee stock purchase plan 21,000   21,000  
Issue stock for covenant waiver (in shares)   873,000    
Issue stock for covenant waiver 300,000   300,000  
Issue stock for warrant exercises (in shares)   36,410,000    
Issue stock for warrant exercises 1,109,000 $ 4,000 1,105,000  
Net loss (8,074,000)     (8,074,000)
Ending Balance (in shares) at Jun. 30, 2020   91,975,000    
Ending Balance at Jun. 30, 2020 5,837,000 $ 9,000 126,989,000 (121,161,000)
Beginning Balance (in shares) at Dec. 31, 2020   189,953,000    
Beginning Balance at Dec. 31, 2020 35,082,000 $ 19,000 178,747,000 (143,684,000)
Equity        
Stock option exercises (in shares)   102,000    
Stock option exercises 333,000   333,000  
Stock-based compensation expense 371,000   371,000  
Issue common stock, net of issuance costs (in shares)   78,000,000    
Issue common stock, net of issuance costs 327,486,000 $ 8,000 327,478,000  
Issue stock for warrant exercises (in shares)   10,739,000    
Issue stock for warrant exercises 9,393,000 $ 1,000 9,392,000  
Net loss (9,947,000)     (9,947,000)
Ending Balance (in shares) at Mar. 31, 2021   278,794,000    
Ending Balance at Mar. 31, 2021 362,718,000 $ 28,000 516,321,000 (153,631,000)
Beginning Balance (in shares) at Dec. 31, 2020   189,953,000    
Beginning Balance at Dec. 31, 2020 $ 35,082,000 $ 19,000 178,747,000 (143,684,000)
Equity        
Stock option exercises (in shares) 162,000      
Net loss $ (28,733,000)      
Ending Balance (in shares) at Jun. 30, 2021   279,054,000    
Ending Balance at Jun. 30, 2021 345,866,000 $ 28,000 518,255,000 (172,417,000)
Beginning Balance (in shares) at Mar. 31, 2021   278,794,000    
Beginning Balance at Mar. 31, 2021 362,718,000 $ 28,000 516,321,000 (153,631,000)
Equity        
Stock option exercises (in shares)   60,000    
Stock option exercises 89,000   89,000  
Stock-based compensation expense 1,758,000   1,758,000  
Issue stock for employee stock purchase plan (in shares)   150,000    
Issue stock for employee stock purchase plan 65,000   65,000  
Issue stock for warrant exercises (in shares)   50,000    
Issue stock for warrant exercises 22,000   22,000  
Net loss (18,786,000)     (18,786,000)
Ending Balance (in shares) at Jun. 30, 2021   279,054,000    
Ending Balance at Jun. 30, 2021 $ 345,866,000 $ 28,000 $ 518,255,000 $ (172,417,000)